ADMA Biologics Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? ADMA Biologics Inc trades at $9.83 (market cap $2.22B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.17. The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QCLN | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $68.47 |
52-Week Low | $7.60 | $36.11 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
QCLN trades at $53.31, up 2.42% on the day, with a bullish technical signal driven by moving averages, though oscillators are neutral. The ETF focuses on clean energy, benefiting from long-term growth themes like rising data center power demand and global energy security investments. Recent news highlights sector momentum but notes regulatory and supply chain pressures.
Outlook is cautiously optimistic, supported by structural energy transition trends, but risks include U.S. permit delays, geopolitical tensions affecting Chinese suppliers, and cost inflation. The absence of key valuation ratios limits fundamental assessment, requiring reliance on sector trends and technical levels for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →